Literature DB >> 9368604

Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes.

J K Voice1, P J Lachmann.   

Abstract

We examined the effect of soluble IgG immune complex (IC) characteristics on the binding of IC to human neutrophils and IC-induced specific granule release of neutrophils via Fc gamma receptors (CD16 and CD32) and complement receptors (CR1 and CR3). A set of soluble IgG IC varying in size, IgG subclass, antigen epitope density and complement (C) incorporation were formed between 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP) coupled to bovine serum albumin (BSA) and chimeric mouse-human anti-NIP monoclonal antibodies (mAb) of all four IgG subclasses. High and low epitope density IC of all four IgG subclasses induced specific granule release with C, but in the absence of C only IgG1 and IgG3 IC were functionally active. The Fc gamma and C receptors responsible for IgG IC-induced specific granule release and IC binding were determined using mAb specific for the ligand binding sites of CD16, CD32 and CR3, and recombinant soluble CR1. Each defined IC displayed a unique pattern of receptor preference, dependent upon subclass and antigenic epitope density. IC binding and IC-induced specific granule release was not mediated by the same receptor, or combination of receptors. High and low epitope density IgG3 IC binding and induction of specific granule release was mediated predominantly via CD16. Other IC subclasses bound differently, i.e. IgG1 IC used CD16 and CR3; IgG2 and IgG4 predominantly used complement receptors; but all three induced specific granule release via CD32. In vivo these results may translate into differential activation of neutrophils by soluble IC dependent upon their characteristics, leading to subtle nuances in the etiology, pathology and control of the immune response in IC-related diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368604     DOI: 10.1002/eji.1830271008

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

Review 1.  Do self-perpetuating B lymphocytes drive human autoimmune disease?

Authors:  J C Edwards; G Cambridge; V M Abrahams
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum.

Authors:  D R Cavanagh; C Dobaño; I M Elhassan; K Marsh; A Elhassan; L Hviid; E A Khalil; T G Theander; D E Arnot; J S McBride
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Aggregation, immune complexes and immunogenicity.

Authors:  Roy Jefferis
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

5.  Whole genome association study results shed light on elusive aetiopathogenesis of systemic lupus erythematosus.

Authors:  V C Kyttaris; K H Costenbader
Journal:  Int J Clin Pract       Date:  2008-06       Impact factor: 2.503

6.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

Review 7.  A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.

Authors:  J M Sailstad; L Amaravadi; A Clements-Egan; B Gorovits; H A Myler; R C Pillutla; S Pursuhothama; M Putman; M K Rose; K Sonehara; L Tang; J T Wustner
Journal:  AAPS J       Date:  2014-03-29       Impact factor: 4.009

8.  Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.

Authors:  J L Teeling; E R De Groot; A J Eerenberg; W K Bleeker; G Van Mierlo; L A Aarden; C E Hack
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.

Authors:  M Holland; P Hewins; M Goodall; D Adu; R Jefferis; C O S Savage
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

10.  Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.

Authors:  Sanjay Khandelwal; Ayiesha Barnes; Lubica Rauova; Amrita Sarkar; Ann H Rux; Serge V Yarovoi; S Sergei Zaitsev; John D Lambris; Sooho S Myoung; Alexandra Johnson; Grace M Lee; Madelaine Duarte; Mortimer Poncz; Gowthami M Arepally; Douglas B Cines
Journal:  Blood       Date:  2021-11-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.